Brief: NeuBase Therapeutics Reports Business Update And Results For Q3 Of FY2022
11/08/2022 14:56
Aug 11 (Reuters) - NeuBase Therapeutics Inc NBSE.O :
* NEUBASE THERAPEUTICS REPORTS BUSINESS UPDATE AND FINANCIAL
RESULTS FOR THE THIRD QUARTER OF FISCAL YEAR 2022
* Q3 LOSS PER SHARE $0.26
* AS OF JUNE 30, 2022, COMPANY HAD CASH AND CASH EQUIVALENTS
OF
APPROXIMATELY $29.8 MILLION
* Q3 EARNINGS PER SHARE VIEW $-0.30 -- REFINITIV IBES DATA
Source text for Eikon: ID:nGNX47xZPS
Further company coverage: NBSE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NeuBase Therapeutics
See all newsBrief: Neubase Therapeutics, On May 2, Was Notified By Nasdaq On Not Regained Compliance With Minimum Bid Price Requirement
Brief: Neubase Therapeutics Announces Receipt Of Notice From Nasdaq
U.S. STOCKS ON THE MOVE-TPG, R1 RCM, Zoom
U.S. STOCKS ON THE MOVE-Micron, Krystal Biotech, Pilgrim's Pride
U.S. STOCKS ON THE MOVE-Domino's Pizza, Voyager, Freshpet